Compugen (CGEN)
(Delayed Data from NSDQ)
$1.92 USD
+0.02 (1.05%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.91 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CGEN 1.92 +0.02(1.05%)
Will CGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CGEN
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Other News for CGEN
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen initiated with bullish view at William Blair
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen announces publication of peer reviewed paper on IL-18
Compugen to Participate in Two Upcoming Investor Conferences